PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy

被引:89
|
作者
Li, Qian [1 ]
Han, Jingjing [1 ]
Yang, Yonglin [2 ]
Chen, Yu [1 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Nanjing, Peoples R China
[2] Nanjing Med Univ, Affiliated Taizhou Peoples Hosp, Dept Infect Dis, Taizhou, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
PD-1; inhibitor; PD-L1; hepatocellular carcinoma; immune checkpoint; tumor immune escape; immunotherapy; REGULATORY T-CELLS; TUMOR-ASSOCIATED MACROPHAGES; TREMELIMUMAB PLUS DURVALUMAB; PD-1; BLOCKADE; OPEN-LABEL; CANCER; EXPRESSION; SORAFENIB; THERAPY; MECHANISMS;
D O I
10.3389/fimmu.2022.1070961
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide. Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a long time, but there are still many shortcomings. In recent years, with the deepening of research on tumor immune microenvironment, researchers have begun to explore new approaches in immunotherapy, and the introduction of immune checkpoint inhibitors has brought fundamental changes to the treatment of HCC. Programmed cell death protein 1 (PD-1) is an immune checkpoint molecule that plays an important role in down-regulating immune system function and promoting tolerance. Programmed cell death ligand 1 (PDL-1) is involved in tumor immune evasion by binding to PD-1, resulting in failure of treatment. Currently, immunotherapy targeting the PD-1/PD-L1 axis has achieved unprecedented success in HCC, but it also faces great challenges, with its low remission rate still to be solved. For most patients with HCC, the PD-1/PD-L1 pathway is not the only rate limiting factor of antitumor immunity, and blocking only the PD-1/PD-L1 axis is not enough to stimulate an effective antitumor immune response; thus, combination therapy may be a better option. In this study, changes in the immune microenvironment of HCC patients were reviewed to clarify the feasibility of anti-PD-1/PD-L1 therapy, and a series of monotherapy and combination therapy clinical trials were summarized to verify the safety and efficacy of this newly developed treatment in patients with advanced HCC. Furthermore, we focused on hyperprogressive disease and drug resistance to gain a better understanding of PD-1/PD-L1 blockade as a promising treatment.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
    Liu, Jinhua
    Chen, Zichao
    Li, Yaqun
    Zhao, Wenjie
    Wu, JiBiao
    Zhang, Zhen
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [2] PD-1/PD-L1 pathway inhibitors in advanced prostate cancer
    Velho, Pedro Isaacsson
    Antonarakis, Emmanuel S.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (05) : 475 - 486
  • [3] Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
    Kudo, Masatoshi
    CANCERS, 2020, 12 (05)
  • [4] Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma
    Chen, Jiaqi
    Zhang, Ding
    Yuan, Ying
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (03) : 579 - 590
  • [5] Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer
    AmeliMojarad, Mandana
    AmeliMojarad, Melika
    Cui, Xiaonan
    PATHOLOGY RESEARCH AND PRACTICE, 2023, 244
  • [6] The future of immunotherapy in advanced renal cell carcinoma: beyond PD-1/PD-L1 inhibitors
    Nuvola, Giacomo
    Mollica, Veronica
    Massari, Francesco
    Suarez, Cristina
    IMMUNOTHERAPY, 2023, 15 (17)
  • [7] Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
    Jilkova, Zuzana Macek
    Aspord, Caroline
    Decaens, Thomas
    CANCERS, 2019, 11 (10)
  • [8] Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway
    Barclay, Jonathan
    Creswell, Joanne
    Leon, Juan
    ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (04): : 393 - 399
  • [9] Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers
    Duruisseaux, Michael
    Rouquette, Isabelle
    Adam, Julien
    Cortot, Alexis
    Cazes, Aurelie
    Gibault, Laure
    Damotte, Diane
    Lantuejoul, Sylvie
    ANNALES DE PATHOLOGIE, 2017, 37 (01) : 61 - 78
  • [10] ENHANCING CANCER CARE WITH IMPROVED CHECKPOINT INHIBITORS: A FOCUS ON PD-1/PD-L1
    Vickram, As
    Shofia, Saghya Infant
    Saravanan, A.
    Sivakumar, Vidhya Lakshmi
    Thamarai, Packiyam
    Sivasubramanian, Manikandan
    Chopra, Shivani
    Chopra, Hitesh
    EXCLI JOURNAL, 2024, 23 : 1303 - 1326